Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Show more
TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.59 | -22.8682170543 | 2.58 | 2.64 | 1.99 | 284906 | 2.29610376 | CS |
4 | -0.26 | -11.5555555556 | 2.25 | 2.72 | 1.99 | 652458 | 2.41811707 | CS |
12 | -2.92 | -59.4704684318 | 4.91 | 4.98 | 1.99 | 476631 | 3.00685588 | CS |
26 | -1.69 | -45.9239130435 | 3.68 | 5.07 | 1.99 | 462762 | 3.53294524 | CS |
52 | -1.86 | -48.3116883117 | 3.85 | 6.35 | 1.99 | 360905 | 3.52188812 | CS |
156 | -6.01 | -75.125 | 8 | 37.55 | 1.99 | 358695 | 6.07207453 | CS |
260 | -6.01 | -75.125 | 8 | 37.55 | 1.99 | 358695 | 6.07207453 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.